Literature DB >> 28107737

Contrast-enhanced spectral mammography (CESM) versus MRI in the high-risk screening setting: patient preferences and attitudes.

Jordana Phillips1, Matthew M Miller2, Tejas S Mehta3, Valerie Fein-Zachary4, Audrey Nathanson5, Wendy Hori6, Rita Monahan-Earley7, Priscilla J Slanetz8.   

Abstract

PURPOSE: Our study evaluates patient preferences toward screening CESM versus MRI.
MATERIALS AND METHODS: As part of a prospective study, high-risk patients had breast MRI and CESM. Patients completed an anonymous survey to evaluate preferences regarding the two modalities.
RESULTS: 88% of participants completed the survey. 79% preferred CESM over MRI if the exams had equal sensitivity. 89% would be comfortable receiving contrast as part of an annual screening test.
CONCLUSION: High-risk populations may accept CESM as a screening exam and may prefer it over screening MRI if ongoing trials demonstrate screening CESM to be clinically non-inferior MRI.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Contrast-enhanced breast magnetic resonance imaging; Contrast-enhanced spectral mammography; High-risk screening

Mesh:

Substances:

Year:  2016        PMID: 28107737     DOI: 10.1016/j.clinimag.2016.12.011

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  11 in total

1.  The emerging role of contrast-enhanced mammography.

Authors:  Andrea Cozzi; Simone Schiaffino; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2019-12

2.  Contrast-enhanced mammography-guided biopsy: technical feasibility and first outcomes.

Authors:  R Alcantara; V Iotti; M Posso; M Pitarch; N Arenas; B Ejarque; G Besutti
Journal:  Eur Radiol       Date:  2022-07-27       Impact factor: 7.034

Review 3.  Contrast-enhanced mammography: past, present, and future.

Authors:  Julie Sogani; Victoria L Mango; Delia Keating; Janice S Sung; Maxine S Jochelson
Journal:  Clin Imaging       Date:  2020-09-19       Impact factor: 1.605

Review 4.  Contrast-enhanced Mammography: State of the Art.

Authors:  Maxine S Jochelson; Marc B I Lobbes
Journal:  Radiology       Date:  2021-03-02       Impact factor: 11.105

5.  Giant epidermal inclusion cyst with infection arising within the breast parenchyma: a case report.

Authors:  Yongxia Zhang; Lei Song; Han Zhang; Fengjie Liu; Guo Hao; Jing Liu; Haizhu Xie; Hao Shi
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

6.  The effectiveness of contrast-enhanced spectral mammography and magnetic resonance imaging in dense breasts.

Authors:  Wojciech Rudnicki; Tomasz Piegza; Natalia Rozum-Liszewska; Mateusz Górski; Tadeusz J Popiela; Pawel Basta; Sylwia Heinze; Elzbieta Luczynska
Journal:  Pol J Radiol       Date:  2021-03-15

7.  Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: A systematic review and meta-analysis.

Authors:  Matteo Basilio Suter; Filippo Pesapane; Giorgio Maria Agazzi; Tania Gagliardi; Olga Nigro; Anna Bozzini; Francesca Priolo; Silvia Penco; Enrico Cassano; Claudio Chini; Alessandro Squizzato
Journal:  Breast       Date:  2020-06-10       Impact factor: 4.380

8.  Low-Dose, Contrast-Enhanced Mammography Compared to Contrast-Enhanced Breast MRI: A Feasibility Study.

Authors:  Paola Clauser; Pascal A T Baltzer; Panagiotis Kapetas; Mathias Hoernig; Michael Weber; Federica Leone; Maria Bernathova; Thomas H Helbich
Journal:  J Magn Reson Imaging       Date:  2020-02-14       Impact factor: 4.813

9.  Contrast-Enhanced Spectral Mammography Versus Ultrasonography: Diagnostic Performance in Symptomatic Patients with Dense Breasts.

Authors:  Zhongfei Lu; Cuijuan Hao; Yan Pan; Ning Mao; Xin Wang; Xundi Yin
Journal:  Korean J Radiol       Date:  2020-04       Impact factor: 3.500

10.  Diagnostic value of the enhancement intensity and enhancement pattern of CESM to benign and malignant breast lesions.

Authors:  Xiaoxiao Chi; Lei Zhang; Dong Xing; Peiyou Gong; Qianqian Chen; Yongbin Lv
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.